Healthcare

ImpediMed Limited (ASX:IPD) is a medical technology company built around a single, focused idea: catching the early signs of lymphoedema before the condition becomes debilitating. Its SOZO platform uses bioimpedance spectroscopy, a painless measurement of the body's fluid and tissue composition, to help clinicians …

Imugene Ltd (ASX:IMU) is an Australian clinical-stage immuno-oncology company that has reshaped itself around a single lead asset: azer-cel, an off-the-shelf, allogeneic CAR T-cell therapy targeting the CD19 protein found on many blood cancers. For investors in Imugene shares, the story in 2026 is …

IODM Ltd (ASX:IOD) is a small Australian software company with an outsized ambition: to become the plumbing that universities and businesses use to collect the money they are owed. The June 2026 quarter delivered its most significant strategic step yet, with the company securing …

Epi-Minder Ltd (ASX:EPI), which trades and is widely known as Epiminder, is an Australian medical technology company trying to change how severe epilepsy is monitored. Its Minder System is an implantable device designed to record brain activity continuously over long periods, giving doctors objective …

Nova Eye Medical Ltd (ASX:EYE) is an Australian ophthalmic device maker that has spent years chasing scale in the United States glaucoma market. On the evidence of its latest figures, the effort is starting to translate into both growth and improving profitability.

Mesoblast (ASX:MSB) traded at A$2.26, down 4.83%, at the time of writing on 14 August 2026 as investors continued assessing the company’s transition from a clinical-stage biotechnologyBusinessinto a commercial cell-therapy company.

Paradigm Biopharmaceuticals (ASX:PAR) has reached a major milestone in the development of Zilosul after completing enrolment in its pivotal Phase 3 knee osteoarthritis trial.